News

Learn more about CTMC’s progress in accelerating cell therapy development and manufacturing to reach patients faster.

Press Releases

In the News

November 5, 2024

Inside Precision Medicine: The End of the Beginning for Cell and Gene Therapy, Part 2

November 4, 2024

Houston Business Journal: More life sciences commercialization on Houston’s horizon, CTMC CEO says

November 1, 2024

The 2024 PharmaVoice 100

October 11, 2024

BioPharma Reporter: Jane Koo on leading regulatory affairs at CTMC: A journey from mAbs to cellular therapies

September 18, 2024

PharmaVoice: Getting IND ready — how companies can avoid common traps

September 8, 2024

Cell&Gene: The Future Of Autologous CAR-T Manufacturing: Balancing Innovation With Improvement

September 1, 2024

Drug Discovery World: Are TILs the next big thing in cancer treatment?

August 7, 2024

Pharma’s Almanac: How are Advancements in Technology Reshaping the Roles and Capabilities of CDMOs and CROs in the Drug Development Life Cycle?

March 14, 2024

First in Human Episode #56 featuring Jason Bock

February 22, 2024

Labiotech: TIL therapies: the impact on cancer research

February 21, 2024

Politico: A new front in the war on cancer

February 21, 2024

Axios: A watershed moment for cancer therapies has arrived

February 21, 2024

PharmaVoice: Behind the breakthrough cancer therapy that just won a historic FDA nod

February 20, 2024

Fox 26 News: FDA approves cell therapy to treat melanoma

February 20, 2024

The Washington Post: Cancer therapy approved by FDA uses body’s own cells as a ‘living drug’

February 19, 2024

European Pharmaceutical Review: Novel immunotherapy approved for melanoma

February 16, 2024

Reuter: US FDA grants accelerated approval for Iovance’s skin cancer cell therapy

February 16, 2024

FDA Greenlights Lifileucel for Unresectable, Metastatic Melanoma Via Accelerated Approval

February 16, 2024

BioSpace: FDA Approves First One-time Cell Therapy for a Solid Tumor

October 24, 2023

Empowered Patient Podcast with Karen Jagoda

October 23, 2023

Investing in a manufacturing infrastructure to harness tumour-infiltrating lymphocytes (TILs) for cancer treatment

October 5, 2023

Tumor Infiltrating Lymphocytes (TILs): Old news or the next big thing in cell therapy?

August 2, 2023

Slice of Healthcare: BioBreakthroughs

May 10, 2023

Innovation Map

December 21, 2022

Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy

September 15, 2022

Ori Biotech taps MD Anderson, National Resilience joint venture to put its automated cell and gene therapy manufacturing tech to the test

June 16, 2022

CTMC, Invectys, and MD Anderson announce strategic collaboration for CAR T cell therapy development 

June 6, 2022

Endpoints News: Resilience forges JV with MD Anderson, readying new cell therapies for cancer

June 3, 2022

Fierce Pharma: National Resilience teams with MD Anderson to add cell therapy JV to its bustling biomanufacturing network.

June 2, 2022

MD Anderson and Resilience launch joint venture to accelerate development and manufacturing of innovative cell therapies for cancer

June 2, 2022

Resilience and MD Anderson Launch Joint Venture to Accelerate Development and Manufacturing of Innovative Cell Therapies for Cancer

April 15, 2021

TIL Therapy: Six Things to Know

November 18, 2020

MD Anderson and Obsidian Therapeutics announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors

January 21, 2020

MD Anderson accelerates cellular therapy programs by buying state-of-art manufacturing facility

View More

For Press Inquiries Contact

[email protected]